KRAS and intestinal neoplasm: Different studies have shown that APC loss alone is insufficient to promote intestinal tumor progression (Anderson et al., 2002, Blaker et al., 2003); additional mutations in other oncogenes such as KRAS and tumor-suppressor genes such as TP53 are required (Fujii et al., 2016).